UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia

Yao,Jie; Luo,Yaosheng; Zeng,Chong; He,Haiyan; Zhang,Xiaoli

doi:10.3892/or.2021.8082

UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia

Authors:
- Jie Yao
- Yaosheng Luo
- Chong Zeng
- Haiyan He
- Xiaoli Zhang
View Affiliations

Affiliations: Department of Laboratory Medicine and Medical Research Center, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong 528300, P.R. China, Department of Laboratory Medicine, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, P.R. China
Published online on: May 18, 2021 https://doi.org/10.3892/or.2021.8082
Article Number: 131

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Macrophage migration inhibitory factor (MIF) has been confirmed as an oncogene in solid tumor development, and its overexpression causes cell proliferation in T acute lymphoblastic leukemia (T‑ALL); however, the underlying mechanisms remain unclear. The overexpression of MIF promotes cellular transformation and proliferation, in part, through interaction with UHRF1. Nevertheless, overexpression of UHRF1 cannot upregulate MIF expression in T‑ALL. New insights into MIF regulation in T‑ALL are imperative to offer the opportunity for therapeutic intervention. In the present study, using RT‑qPCR, western blot analysis, confocal microscopy and RNA sequence, we report the identification and validation of UHRF1 as a negative regulator of MIF, which functions to downregulate MIF expression by binding to the CATT repeat sequence of the MIF promoter. By contrast, HMG‑box protein 1 (HBP1) functions as a positive regulator of MIF. Moreover, we demonstrated that HBP1 suppressive signaling is reduced by UHRF1 through promotion of the interaction between MIF and HBP1. MIF deficiency caused by UHRF1 knockdown resulted in enhanced apoptosis in T‑ALL as compared with that caused by decreased MIF or increased HBP1 expression alone. These results identify UHRF1 as a key regulator of MIF transcription in T‑ALL, although these transcription factors possess opposite regulatory functions. Thus, this mechanism may provide insight into how to effectively prevent MIF‑dependent oncogenic activity. Finally, T‑ALL mice possessing high HBP1 or low UHRF1 expression levels are associated with longer survival as compared with control mice, with UHRF1‑knockdown mice living the longest. Taken together, these findings indicate that MIF and its regulators are potential treatment targets and biomarkers for the prediction of prognosis in T‑ALL.

View Figures

View References

1	Kang I and Bucala R: The immunobiology of MIF: Function, genetics and prospects for precision medicine. Nat Rev Rheumatol. 15:427–437. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bloom J, Sun S and Al-Abed Y: MIF, a controversial cytokine: A review of structural features, challenges, and opportunities for drug development. Expert Opin Ther Targets. 20:1463–1475. 2016. View Article : Google Scholar : PubMed/NCBI
3	Liu A, Bao F and Voravuthikunchai SP: CATT polymorphism in MIF gene promoter is closely related to human pulmonary tuberculosis in a southwestern China population. Int J Immunopathol Pharmacol. May 29–2018.(Epub ahead of print). doi: 10.1177/2058738418777108.
4	Matia-García I, Salgado-Goytia L, Muñoz-Valle JF, García-Arellano S, Hernández-Bello J, Salgado-Bernabé AB and Parra-Rojas I: Macrophage migration inhibitory factor promoter polymorphisms (−794 CATT 5–8 and −173 G>C): Relationship with mRNA expression and soluble MIF levels in young obese subjects. Dis Markers. 2015:4612082015. View Article : Google Scholar
5	Yao J, Leng L, Sauler M, Fu W, Zheng J, Zhang Y, Du X, Yu X, Lee P and Bucala R: Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus. J Clin Invest. 126:732–744. 2016. View Article : Google Scholar : PubMed/NCBI
6	Mousli M, Hopfner R, Abbady AQ, Monté D, Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 89:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
7	Abbady AQ, Bronner C, Trotzier MA, Hopfner R, Bathami K, Muller CD, Jeanblanc M and Mousli M: UHRF1 expression is downregulated in apoptosis-induced Jurkat cells. Ann N Y Acad Sci. 1010:300–303. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C and Mousli M: The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer. Oncotarget. 8:51946–51962. 2017. View Article : Google Scholar : PubMed/NCBI
9	Chen YC, Zhang XW, Niu XH, Xin DQ, Zhao WP, Na YQ and Mao ZB: Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer. Oncogene. 29:3067–3078. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bollaert E, Johanns M, Herinckx G, de Rocca Serra A, Vandewalle VA, Havelange V, Rider MH, Vertommen D and Demoulin JB: HBP1 phosphorylation by AKT regulates its transcriptional activity and glioblastoma cell proliferation. Cell Signal. 44:158–170. 2018. View Article : Google Scholar : PubMed/NCBI
11	Bollaert E, de Rocca Serra A and Demoulin JB: The HMG box transcription factor HBP1: A cell cycle inhibitor at the crossroads of cancer signaling pathways. Cell Mol Life Sci. 76:1529–1539. 2019. View Article : Google Scholar : PubMed/NCBI
12	Li H, Wang W, Liu X, Paulson KE, Yee AS and Zhang X: Transcriptional factor HBP1 targets P16(INK4A), upregulating its expression and consequently is involved in Ras-induced premature senescence. Oncogene. 29:5083–5094. 2010. View Article : Google Scholar : PubMed/NCBI
13	Fukaya R, Ohta S, Yaguchi T, Matsuzaki Y, Sugihara E, Okano H, Saya H, Kawakami Y, Kawase T, Yoshida K and Toda M: MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Res. 76:2813–2823. 2016. View Article : Google Scholar : PubMed/NCBI
14	Sharaf-Eldein M, Elghannam D, Elderiny W and Abdel-Malak C: Prognostic implication of MIF gene expression in childhood acute lymphoblastic leukemia. Clin Lab. 64:1429–1437. 2018. View Article : Google Scholar : PubMed/NCBI
15	Kumar S, O'Malley J, Chaudhary AK, Inigo JR, Yadav N, Kumar R and Chandra D: Hsp60 and IL-8 axis promotes apoptosis resistance in cancer. Br J Cancer. 121:934–943. 2019. View Article : Google Scholar : PubMed/NCBI
16	Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, Sironi S, Sotlar K, Horny HP, Deniffel C, Drolle H and Fiegl M: IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep. 5:184112015. View Article : Google Scholar : PubMed/NCBI
17	Vijay V, Miller R, Vue GS, Pezeshkian MB, Maywood M, Ast AM, Drusbosky LM, Pompeu Y, Salgado AD, Lipten SD, et al: Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leuk Res. 84:1061802019. View Article : Google Scholar : PubMed/NCBI
18	Bilsborrow JB, Doherty E, Tilstam PV and Bucala R: Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets. 23:733–744. 2019. View Article : Google Scholar : PubMed/NCBI
19	Noe JT and Mitchell RA: MIF-dependent control of tumor immunity. Front Immunol. 11:6099482020. View Article : Google Scholar : PubMed/NCBI